Spots Global Cancer Trial Database for Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients

Official Title: Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients

Study ID: NCT06310902

Conditions

Pancreatic Neoplasms

Interventions

Single-cell Sequencing Analysis

Study Description

Brief Summary: Preoperative neoadjuvant chemotherapy is widely used in treating patients with borderline resectable pancreatic cancer (BRPC). However, there are limitations in this field. Treatment strategies and definitions for BRPC patients differ, and the efficacy and prognosis of neoadjuvant chemotherapy vary greatly.This study aims to utilize single-cell sequencing technology to investigate in-depth the composition and interactions of the tumor microenvironment in patients from the surgical-only group and the preoperative neoadjuvant chemotherapy group.

Detailed Description: